Active, not recruitingPhase 3NCT05662319
A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia
Studying Hemophilia B
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sanofi
- Principal Investigator
- Clinical Sciences & OperationsSanofi
- Intervention
- Fitusiran(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 12 years · MALE
- Timeline
- 2023 – 2029
Study locations (30)
- Center for Inherited Blood Disorders (CIBD) Site Number : 8400012, Orange, California, United States
- M Health Fairview University of Minnesota Medical Center - West Bank- Site Number : 8400016, Minneapolis, Minnesota, United States
- Hackensack University Site Number : 8400009, Hackensack, New Jersey, United States
- Northwell Health Hemostasis and Thrombosis Center Site Number : 8400015, New Hyde Park, New York, United States
- University Hospitals of Cleveland Site Number : 8400001, Cleveland, Ohio, United States
- UPMC Children's Hospital of Pittsburgh-4401 Penn Ave Site Number : 8400017, Pittsburgh, Pennsylvania, United States
- Children's Medical Center Dallas- Site Number : 8400018, Dallas, Texas, United States
- Gulf States Hemophilia and Thrombophilia Center- Site Number : 8400002, Houston, Texas, United States
- Investigational Site Number : 1240001, Hamilton, Ontario, Canada
- Investigational Site Number : 1240002, Hamilton, Ontario, Canada
- Investigational Site Number : 1240004, Toronto, Ontario, Canada
- Investigational Site Number : 1560003, Beijing, China
- Investigational Site Number : 1560001, Guangzhou, China
- Investigational Site Number : 1560002, Jinan, China
- Investigational Site Number : 2500003, Le Kremlin-Bicêtre, France
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05662319 on ClinicalTrials.govOther trials for Hemophilia B
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07285460A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BSanofi
- RECRUITINGPHASE3NCT07080905Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia BCSL Behring
- RECRUITINGPHASE1, PHASE2NCT06611436BeCoMe-9: A Clinical Study of BE-101 for the Treatment of Adults With Moderately Severe or Severe Hemophilia BBe Biopharma
- ACTIVE NOT RECRUITINGPHASE3NCT06569108Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without InhibitorsSuzhou Alphamab Co., Ltd.
- RECRUITINGPHASE3NCT06003387Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)CSL Behring
- RECRUITINGNCT06008938An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia BCSL Behring
- RECRUITINGNANCT05630651The Efficacy and Safety of ZS801 in Chinese Hemophilia B Patients.Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1NCT05709288Gene Therapy for Hemophilia B Patients Aged 12-18 Years OldInstitute of Hematology & Blood Diseases Hospital, China